🚀 VC round data is live in beta, check it out!
Bioton Valuation Multiples
Discover revenue and EBITDA valuation multiples for Bioton and similar public comparables like Laboratorios Richmond, Nyrada, Actinogen Medical, Anixa Biosciences and more.
Bioton Overview
About Bioton
Bioton SA is a Poland based company engaged in the principal business activity of manufacturing medicines and pharmaceutical preparations and production of pharmaceutical substances. The products of the company include recombinant human insulin in pharmaceutical substance form and as preparations for injections; glimepiride, an oral hypoglycemic drug; and metformin, an oral hypoglycemic drug. Its products line focuses on diet supplements, products for particular nutritional uses and cosmetics dedicated to patients with certain health problems. The group operates in Poland and internationally, of which majority of the revenue is derived from Poland.
Founded
1989
HQ
Employees
579
Website
Sectors
Financials (FY)
EV
$114M
Bioton Financials
Bioton reported last fiscal year revenue of $79M and EBITDA of $14M.
In the same fiscal year, Bioton generated $26M in gross profit, $14M in EBITDA, and $944K in net income.
Revenue (LTM)
Bioton P&L
In the most recent fiscal year, Bioton reported revenue of $79M and EBITDA of $14M.
Bioton expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $79M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $26M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 32% | XXX | XXX | XXX |
| EBITDA | — | XXX | $14M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 18% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 5% | XXX | XXX | XXX |
| Net Profit | — | XXX | $944K | XXX | XXX | XXX |
| Net Margin | — | XXX | 1% | XXX | XXX | XXX |
| Net Debt | — | — | $9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Bioton Stock Performance
Bioton has current market cap of $100M, and enterprise value of $114M.
Market Cap Evolution
Bioton's stock price is $1.17.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $114M | $100M | -0.8% | XXX | XXX | XXX | $0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBioton Valuation Multiples
Bioton trades at 1.4x EV/Revenue multiple, and 8.0x EV/EBITDA.
EV / Revenue (LTM)
Bioton Financial Valuation Multiples
As of April 18, 2026, Bioton has market cap of $100M and EV of $114M.
Equity research analysts estimate Bioton's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bioton has a P/E ratio of 106.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $100M | XXX | $100M | XXX | XXX | XXX |
| EV (current) | $114M | XXX | $114M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 8.0x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 29.4x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 4.5x | XXX | XXX | XXX |
| P/E | — | XXX | 106.3x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 42.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Bioton Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Bioton Margins & Growth Rates
Bioton's revenue in the last fiscal year grew by 36%.
Bioton's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Bioton Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 36% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 61% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 13% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 13% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 28% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Bioton Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Bioton | XXX | XXX | XXX | XXX | XXX | XXX |
| Laboratorios Richmond | XXX | XXX | XXX | XXX | XXX | XXX |
| Nyrada | XXX | XXX | XXX | XXX | XXX | XXX |
| Actinogen Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Anixa Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Inovio Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bioton M&A Activity
Bioton acquired XXX companies to date.
Last acquisition by Bioton was on XXXXXXXX, XXXXX. Bioton acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Bioton
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBioton Investment Activity
Bioton invested in XXX companies to date.
Bioton made its latest investment on XXXXXXXX, XXXXX. Bioton invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Bioton
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Bioton
| When was Bioton founded? | Bioton was founded in 1989. |
| Where is Bioton headquartered? | Bioton is headquartered in Poland. |
| How many employees does Bioton have? | As of today, Bioton has over 579 employees. |
| Is Bioton publicly listed? | Yes, Bioton is a public company listed on Warsaw Stock Exchange. |
| What is the stock symbol of Bioton? | Bioton trades under BIO ticker. |
| When did Bioton go public? | Bioton went public in 2005. |
| Who are competitors of Bioton? | Bioton main competitors are Laboratorios Richmond, Nyrada, Actinogen Medical, Anixa Biosciences. |
| What is the current market cap of Bioton? | Bioton's current market cap is $100M. |
| What is the current revenue of Bioton? | Bioton's last fiscal year revenue is $79M. |
| What is the current EV/Revenue multiple of Bioton? | Current revenue multiple of Bioton is 1.4x. |
| Is Bioton profitable? | No, Bioton is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.